Is a complete BTAI research report available?

No complete published report is available for BioXcel Therapeutics, Inc. (BTAI) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

BioXcel Therapeutics, Inc. (BTAI)

NASDAQ: BTAI · USD

$0.79

-0.01 (-1.2%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first BTAI analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	24.5M
Revenue (ttm)	680K
Net income (ttm)	-75.3M
EPS (ttm)	-$4.46
Shares out	30.9M
Volume	763,721
Beta	0.27
Price target	$14.0	+1665.9%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 680K
Net income (ttm): -75.3M
EPS (ttm): -$4.46
Market cap: 24.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All BTAI indicators

Market & fundamental data

Available fields

205

Groups with data

Currency

USD

Showing 205 of 205 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001720893
Company name	BioXcel Therapeutics, Inc.
Country	United States
Country code	US
Cusip	09075P204
Employees	29
Employees Change	-8%
Employees Change Percent	-21.62
Enterprise value	$107.6M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
Industry PE	114.9
Industry PE Fwd	13.93
IPO Date	2018-03-08
Isin	US09075P2048
Last refreshed	2026-07-31
Market cap	$24.5M
Market cap category	Nano-Cap
Price	$0.79
Price currency	USD
Rev Per Employee	23,448.28x
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	BTAI
Website	https://www.bioxceltherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-307.74%
EV Sales Forward	78.88x
EV/Sales	158.22x
FCF yield	-234.4%
P/S ratio	36x
PS Forward	17.95x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-23,204.13%
EBITDA Margin	-23,074.77%
Gross margin	36.32%
Gross Profit	$247,000
Gross Profit Growth3 Y	-23.51%
Net Income	$-75.3M
Net Income Growth Years	0%
Pretax Margin	-11,078.53%
Profit Per Employee	$-2.6M
ROA	-86.77
Roa5y	-59.33
ROCE	241.2
ROIC	-602.8

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-50.16%
Cagr3y	-82.7%
Cagr5y	-71.45%
EPS Growth Quarters	10
EPS Growth Years	2
Revenue Growth	-63.28x
Revenue Growth Q	22.62x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	5.38x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.02
Assets	$34M
Cash	$17.2M
Current Assets	$33.9M
Current Liabilities	$55M
Debt	$100.3M
Equity	$-105.5M
Interest Coverage	-2.94
Liabilities	$139.6M
Long Term Assets	$117,000
Long Term Liabilities	$84.6M
Net Cash	$-83.1M
Net Cash By Market Cap	$-340
Tangible Book Value	$-105.5M
Tangible Book Value Per Share	$-3.9
WACC	12.01

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.62
Inventory Turnover	0.76
Net Working Capital	$-15.8M
Quick ratio	0.32
Working Capital	$-21.1M
Working Capital Turnover	$-0.15

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-417.97%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-50.14%
200-day SMA	1.52
3Y total return	-99.48%
50-day SMA	1.09
50-day SMA vs 200-day SMA	50under200
5Y total return	-99.81%
All Time High	1,144
All Time High Change	-99.93%
All Time High Date	2020-07-20
All Time Low	0.74
All Time Low Change	7.64%
All Time Low Date	2026-07-09
ATR	0.09
Beta	0.27
Beta1y	3.79
Beta2y	2.24
Ch YTD	-50.45
High	0.81
High52	8.08
High52 Date	2025-08-12
High52ch	-90.19%
Low	0.75
Low52	0.74
Low52 Date	2026-07-09
Low52ch	7.64%
Ma50ch	-27.13%
Premarket Change Percent	-0.29
Premarket Price	$0.8
Premarket Volume	46,362
Price vs 200-day SMA	-47.84%
RSI	35.14
RSI Monthly	34.34
RSI Weekly	34.7
Sharpe ratio	0.09x
Sortino ratio	0.24
Total Return	-417.97%
Tr YTD	-50.45
Tr1m	-43.37%
Tr1w	-8.9%
Tr3m	-23.77%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	2
Analyst Price Target Top	$3
Analyst Ratings	Buy
Analyst Ratings Top	Hold
Earnings EPS Estimate	$-0.56
Earnings Revenue Estimate	203,408x
Earnings Revenue Estimate Growth	69.51x
Operating Income	$-50.4M
Operating margin	-7,410.4
Price target	$14
Price Target Change	$1,666
Price Target Change Top	$278

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	26,355,139%
Float Percent	85.35%
Net Borrowing	-8,108,000
Shares Insiders	0.63%
Shares Institutions	5.67%
Shares Out	30,877,605
Shares Qo Q	7.85%
Shares Yo Y	417.97%
Short Float	15.34%
Short Ratio	2.67
Short Shares	13.1

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-60.4M
Adjusted OCF	-60,403,000
Average Volume	1,457,365.2x
Bv Per Share	-3.9
Ch1m	-43.37
Ch1w	-8.9
Ch1y	-50.14
Ch3m	-23.77
Ch3y	-99.48
Ch5y	-99.81
Ch6m	-51.06
Change	-1.2%
Change From Open	0.35
Close	0.8
Days Gap	-1.55
Depreciation Amortization	282,000
Dollar Volume	605,478
Earnings Date	2026-08-14
Earnings Time	bmo
EBIT	$-50.6M
EBITDA	$-50.3M
EPS	$-4.46
F Score	3
FCF	$-57.4M
FCF EV Yield	-53.33x
FCF Per Share	$-1.86
Financing CF	43,548,000
Fiscal Year End	December
Founded	2,017
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-15
Last Report Date	2026-03-31
Last Split Date	2025-02-10
Last Split Type	Reverse
Last10k Filing Date	2026-03-27
Ma150	1.35
Ma150ch	-41.27%
Ma20	0.91
Ma20ch	-13.14%
Net CF	-13,833,000
Next Earnings Date	2026-08-11
Open	0.79
Optionable	No
Position In Range	69.45
Post Close	0.79
Postmarket Change Percent	2.16
Postmarket Price	$0.81
Ppne	117,000
Pre Close	0.8
Price Date	2026-07-30
Relative Volume	0.52x
Revenue	680,000x
SBC By Revenue	444.41x
Share Based Comp	3,022,000
Tr6m	-51.06%
Us State	Connecticut
Volume	763,721
Z Score	-35.62

BioXcel Therapeutics, Inc. (BTAI)

Coverage state: Market snapshot only — no published research

Generate the first BTAI analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · BTAI

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BTAI indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on BTAI

Frequently asked questions